What are the clinical manifestations of glucose‑6‑phosphate dehydrogenase deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Manifestations of G6PD Deficiency

Most individuals with G6PD deficiency remain completely asymptomatic throughout their entire lives until exposed to an oxidative trigger. 1, 2

Acute Hemolytic Crisis (Most Common Presentation)

The hallmark clinical presentation occurs when patients encounter oxidative stressors, triggering red blood cell destruction: 1, 2

Cardinal Symptoms of Acute Hemolysis

  • Dark urine (hemoglobinuria) - often the first noticed symptom 3
  • Sudden fatigue or pallor from acute anemia 3
  • Jaundice (yellowing of skin and eyes) 1, 2
  • Back or abdominal pain 1
  • Anemia with associated weakness 1, 2

Common Triggers for Hemolytic Episodes

The three major precipitants that unmask G6PD deficiency are: 1, 2

  • Medications - particularly dapsone, primaquine, methylene blue, rasburicase, and pegloticase 3, 1
  • Infections - any significant infection can trigger hemolysis 1, 2
  • Fava beans (broad beans) - the classic presentation known as "favism" 1, 2, 4

Neonatal Presentation

Neonatal hyperbilirubinemia is a critical early manifestation that requires urgent recognition to prevent kernicterus. 2

  • Affected newborns may develop severe jaundice requiring phototherapy or exchange transfusion 2
  • This can occur even without obvious oxidative exposure 2

Severity Variations by Genetic Variant

The clinical severity depends heavily on which genetic mutation is present: 3, 5

Mediterranean Variant (G6PD-B⁻)

  • Causes severe, potentially life-threatening hemolysis 3
  • Predominantly affects individuals from Mediterranean regions, India, and Southeast Asia 3, 5
  • Requires strict avoidance of all oxidant medications 3

African Variant (GdA-)

  • Typically causes milder, self-limited hemolysis 3
  • Found in 10-15% of individuals of African descent 3
  • Less severe reactions compared to Mediterranean variant 3

Chronic Hemolysis (Rare)

A small subset of patients with sporadic gene mutations experience ongoing chronic hemolysis rather than episodic acute crises, though this variant is uncommon. 2

Asymptomatic Carriers

Heterozygous females and males with milder variants may never develop symptoms if they avoid oxidative triggers. 1, 2 This represents the majority of G6PD-deficient individuals worldwide, explaining why many cases remain undiagnosed until an acute crisis occurs. 1

Critical Clinical Pitfall

Children of any age can develop hemolysis from contraindicated medications, and the same restrictions that apply to adults must be observed in pediatric patients. 3 Healthcare providers must maintain high clinical suspicion in at-risk ethnic populations (Mediterranean, African, Indian, or Southeast Asian descent) who present with unexplained hemolysis, especially following new medication exposure or infection. 5, 1

References

Research

Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018

Research

Diagnosis and management of G6PD deficiency.

American family physician, 2005

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

G6PD Deficiency Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the presentation, diagnosis, complications, and treatment of Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
Is Buscopan (Hyoscine) safe in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency?
Can benzodiazepines (benzos) trigger hemolysis in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
Can butamirate be given to a patient with Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
I am a 30‑year‑old man, 6′5″, 322 lb, with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency on a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, presenting with progressive proximal muscle weakness, creatine kinase (CK) 527 U/L, antinuclear antibody (ANA) 1:160 speckled pattern, anti‑U1‑RNP antibodies 86 U (reference < 20), and a negative extractable nuclear antigen (ENA) panel—does this suggest cancer, and what is the most likely diagnosis and appropriate next steps?
How should an adult with a fusiform abdominal aortic aneurysm (AAA) be medically managed, surveilled, and when is surgical or endovascular aneurysm repair (EVAR) indicated?
What are the intrinsic and extrinsic causes of hemolytic anemia?
Should a patient who has received annual intravenous zoledronic acid (Reclast) for five years and whose repeat dual‑energy X‑ray absorptiometry still shows osteoporosis continue the medication?
Can vortioxetine cause tachycardia in adults (including older adults), especially those with pre‑existing cardiac disease, hypertension, or arrhythmias?
How do congestive hepatopathy and shock liver differ in etiology, clinical presentation, laboratory findings, imaging characteristics, and management?
What is the treatment for neurogenic thoracic outlet syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.